Market Snapshot: Obesity Space Is ‘Not For The Faint of Heart’

Several anti-obesity treatments are in the home stretch of late-stage development, promising to rev up a stagnant market and satisfy pent-up demand. But there's an elephant in the weight loss room - nobody seems to know who will pick up the tab for new drugs

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet